Author

James O. Lindsay

Stool tests in nutrition-adjust the test to the disease-and patient
Stool tests in nutrition-adjust the test to the disease-and patient

James O. Lindsay

Guiding the way through novel therapies in ulcerative colitis
Guiding the way through novel therapies in ulcerative colitis

James O. Lindsay

Webinar: COVID-19 & Digestive Health #1 | IBD & Endoscopy
Webinar: COVID-19 & Digestive Health #1 | IBD & Endoscopy

James O. Lindsay  et al.

Therapeutic Strategies in Crohn’s Disease: Does Pathophysiology Matter? (Takeda Pharmaceuticals International AG)
Therapeutic Strategies in Crohn’s Disease: Does Pathophysiology Matter? (Takeda Pharmaceuticals International AG)

James O. Lindsay  et al.

A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE
A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE

Targeting IL-23: emerging possibilities in the management of Crohn’s disease (AbbVie) - Inhibition of IL-23: a pathway worth exploring
Targeting IL-23: emerging possibilities in the management of Crohn’s disease (AbbVie) - Inhibition of IL-23: a pathway worth exploring

James O. Lindsay

A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE
A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE

James O. Lindsay  et al.

ASSOCIATION OF BASELINE IL-23 PATHWAY-ASSOCIATED GENE EXPRESSION WITH RISANKIZUMAB-INDUCED CLINICAL REMISSION AND ENDOSCOPIC RESPONSE AT WEEK 12 IN CROHN’S DISEASE PATIENTS
ASSOCIATION OF BASELINE IL-23 PATHWAY-ASSOCIATED GENE EXPRESSION WITH RISANKIZUMAB-INDUCED CLINICAL REMISSION AND ENDOSCOPIC RESPONSE AT WEEK 12 IN CROHN’S DISEASE PATIENTS

James O. Lindsay  et al.

Exploring the evolution of care in Crohn’s disease (Janssen)
Exploring the evolution of care in Crohn’s disease (Janssen)

James O. Lindsay  et al.

Preventive and screening measures
Preventive and screening measures

James O. Lindsay

UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY
UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY

James O. Lindsay  et al.

Biologics vs. small molecules: Who first?
Biologics vs. small molecules: Who first?

James O. Lindsay  et al.

A RETROSPECTIVE COHORT STUDY TO COMPARE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) INFLIXIMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
A RETROSPECTIVE COHORT STUDY TO COMPARE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) INFLIXIMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

James O. Lindsay  et al.

UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH
UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH

James O. Lindsay  et al.

ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB
ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB

James O. Lindsay  et al.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

James O. Lindsay  et al.

A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

James O. Lindsay  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

James O. Lindsay  et al.

IMPACT OF CONCOMITANT THIOPURINE ON THE EFFICACY AND SAFETY OF FILGOTINIB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
IMPACT OF CONCOMITANT THIOPURINE ON THE EFFICACY AND SAFETY OF FILGOTINIB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

James O. Lindsay  et al.

Item 1 - 20 / 24
1
2